NCT06217952View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 5, 2023

Primary Completion Date

August 6, 2023

Study Completion Date

August 6, 2023

Conditions
Cystic Fibrosis
Interventions
DRUG

SPL84

SPL84 solution for nebulization

OTHER

Placebo

Placebo solution for nebulization

Trial Locations (1)

Unknown

Hadassah Ein Kerem Hospital Clinical Research Center, Jerusalem

All Listed Sponsors
lead

SpliSense Ltd.

INDUSTRY